Financings Of The Fortnight Puts On The Weight
This article was originally published in The Pink Sheet Daily
Executive Summary
Plus news on recent financing activity by Vivus, Aragon, 4s3 Bioscience and Amicus.
You may also be interested in...
Eyeing Both A Partnership And An IPO, Aragon Takes $42M Series C
A well-connected fund that invests on behalf of a group of high-net-worth investors provides cash to complete a Phase II trial on prostate cancer drug ARN-509, and bring a breast cancer drug into the clinic.
Qnexa REMS Should Deter Off-Label Use Of Components, But Not Place Undue Burden
The Endocrinologic and Metabolic Drugs Advisory Committee voted 20-2 in favor of approving the combination of phentermine and topiramate for weight loss during its second review of Vivus’ application.
Panel Favors Qnexa Approval, Given Strong Efficacy, Certainty Of Post-Approval CV Study
Office of New Drugs Director John Jenkins reassured panel members of the agency’s ability to assess civil penalties or cite a drug for misbranding if sponsors fail to meet post-market study obligations.